Dabrafenib

• Bleeding can occur anywhere in the stomach or brain during treatment with dabrafenib and patients should be monitored for such symptoms or signs. • Treatment with dabrafenib can be stopped temporarily during bleeding episodes and can be restarted with the lowest effective dose.‍‍‍‍‍‍​​​‍​​​​​​ Permanently discontinue treatment if the bleeding is severe. • Cardiomyopathy or disease of the heart muscle making the pumping of the blood harder is reported in patients taking dabrafenib capsules. So, patients must get an ECG or a Multigated Acquisition (MUGA) scan before being given dabrafenib, and one month after taking dabrafenib, followed by regular tests and scans at every three-month interval. • Monitor patients for any symptoms and signs of uveitis such as changes in vision, sensitivity to light, and eye pain and adjust treatment with dabrafenib or permanently discontinue depending on the eye damage. • Episodes of high fever can occur along with chills, low blood pressure and dehydration during dabrafenib treatment. In such cases, fever-reducing pills such as paracetamol along with steroid medications can be taken with dabrafenib when there is no evidence of infection. • Destruction of red blood cells or hemolytic anemia can occur when dabrafenib is given to patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. So, patients must be monitored carefully to avoid serious complications. • The skin should be checked regularly every two months during dabrafenib therapy and for at least six months after the treatment is stopped.